Glipizide

格列吡嗪

Report date: 2022/02/21 15:12:58
NME

Base Information

Drug NameGlipizide
Drug Alias Name吡磺环已脲glipizide格列甲嗪Glipizidum格列吡秦 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSulfonylurea receptor modulators
TargetsSulfonylurea receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Pancreatic NeoplasmsCarcinoma, Pancreatic Ductal
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date1984/05/08
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, BerkeleyShanghai Medical No 15 Pharmaceutical Factory Co Ltd
Inactive CompaniesSandozPfizer Inc
Active IndicationsDiabetes Mellitus, Type 2Pancreatic NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeA10BB07
Related LinksWikipediaDrugBankKEGG